Navigation Links
Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
Date:11/2/2009

NEW BRUNSWICK, N.J., Nov. 2 /PRNewswire/ -- In a joint statement, Czura Thornton's founders Tony Czura and Nick Thornton said: "We are delighted to augment our Life Sciences Group with Clearstone Central Laboratories and the deep expertise of the people there. We intend to maintain the integrity of the operational teams and continue to invest in strengthening the company's focus on exceptional client service. Combined with our renewed focus on the consistent delivery of high quality service, flexibility and responsiveness that private ownership allows, we look forward to expanding Clearstone's market reach."

Clearstone Central Laboratories, formerly MDS Pharma Services' Central Labs business, is among the largest private Global Central Laboratory companies solely focused on clinical research and cardiac services. Through a unique network of wholly owned CAP certified laboratories, Clearstone offers central laboratory services spanning the clinical development lifecycle. With strategically placed laboratories in the Americas, Europe and Asia, all are equivalently equipped and harmonized to provide consistent, dependable results across programs, study phases and geographies.

In addition, Clearstone leverages information technology tools aligned with value add project management principles for managing global clinical trials. Each of its laboratories utilizes the company's centralized APOLLO-CLPM(TM) (Central Laboratory Protocol Manager) enabling Clearstone project management teams with real-time visibility to component and test level data. Viq Pervaaz, Vice President of Global Project Management commented, "We facilitate our strong project management and data management teams with innovative technology solutions and an advanced web based protocol management system to meet the needs of our clients."

About Czura Thornton: Czura Thornton is a private investment group that was founded by Tony Czura and Nick Thornton in 2003. The group, which owns leading CRO Chiltern (www.chiltern.com), has interests in the life sciences, international trade, property and automotive sectors. In particular Messrs Czura and Thornton have extensive international experience in the laboratory and CRO sectors. For further information see www.czurathornton.com.

About Clearstone Central Laboratories: Clearstone Central Laboratories offers clinical laboratory and cardiac services solutions spanning the globe with 600 people and 6 facilities in Paris, Hamburg, Toronto, New Jersey, *Beijing and Singapore.

For further information see www.clearstonelabs.com.

*The acquisition of the China business is pending subject to receipt of required Chinese governmental approvals.

SOURCE Clearstone Central Laboratories


'/>"/>
SOURCE Clearstone Central Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
2. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
5. Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
8. invivodata Recognized as One of Pittsburghs Fastest Growing Private Companies
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... announced the addition of the "Rheumatoid Arthritis Drugs Price Analysis and ... latest research Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016, provides ... The research answers the following questions: ... attributes? How are they positioned in the Global Rheumatoid Arthritis market? ...
(Date:2/28/2017)... 2017 Medical robots market is projected to ... billion in 2016, growing at a CAGR of 21.1% ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... therapy, technological advancements, increase in funding for medical robots ... growing hospital investments are the key factors driving the ...
(Date:2/28/2017)... , Feb. 27, 2017  Summary This ... understand Syngenta and its partnering interests and activities since ... Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... & Scientific Session on September 16-17 in Greenville, SC at the Bon Secours ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... Inc., a healthcare automation intelligence company based in New York. , “Ensuring an ... the provider’s workflow remains unaltered. Those two fundamental reasons are the reasons this ...
(Date:2/27/2017)... ... February 27, 2017 , ... It’s ... strength, which often leads to a host of health issues, including urinary incontinence. ... Geriatrics Society discovered that good overall muscle strength in older women, particularly ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare ... for a company involved in the underground testing of nuclear weapons. Years later, when ... Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
Breaking Medicine News(10 mins):